Gilead Sciences acquires German biotech company for $1.39 billion

The acquisition aims to boost Gilead’s development and commercialization of therapeutics for treating the chronic hepatitis delta virus.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.